JP7808059B2 - 可溶型ｃｌｅｃ２を用いた癌患者における血栓症リスクの予測方法 - Google Patents

可溶型ｃｌｅｃ２を用いた癌患者における血栓症リスクの予測方法

Info

Publication number
JP7808059B2
JP7808059B2 JP2022575626A JP2022575626A JP7808059B2 JP 7808059 B2 JP7808059 B2 JP 7808059B2 JP 2022575626 A JP2022575626 A JP 2022575626A JP 2022575626 A JP2022575626 A JP 2022575626A JP 7808059 B2 JP7808059 B2 JP 7808059B2
Authority
JP
Japan
Prior art keywords
cancer
thrombosis
concentration
risk
clec2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022575626A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022154045A5 (https=
JPWO2022154045A1 (https=
Inventor
幸彦 藤井
雅英 川村
嘉門 白川
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PHC Corp
Original Assignee
PHC Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PHC Corp filed Critical PHC Corp
Publication of JPWO2022154045A1 publication Critical patent/JPWO2022154045A1/ja
Publication of JPWO2022154045A5 publication Critical patent/JPWO2022154045A5/ja
Application granted granted Critical
Publication of JP7808059B2 publication Critical patent/JP7808059B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/226—Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2022575626A 2021-01-13 2022-01-13 可溶型ｃｌｅｃ２を用いた癌患者における血栓症リスクの予測方法 Active JP7808059B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021003671 2021-01-13
JP2021003671 2021-01-13
PCT/JP2022/000891 WO2022154045A1 (ja) 2021-01-13 2022-01-13 可溶型ｃｌｅｃ２を用いた癌患者における血栓症リスクの予測方法

Publications (3)

Publication Number Publication Date
JPWO2022154045A1 JPWO2022154045A1 (https=) 2022-07-21
JPWO2022154045A5 JPWO2022154045A5 (https=) 2024-10-29
JP7808059B2 true JP7808059B2 (ja) 2026-01-28

Family

ID=82448474

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022575626A Active JP7808059B2 (ja) 2021-01-13 2022-01-13 可溶型ｃｌｅｃ２を用いた癌患者における血栓症リスクの予測方法

Country Status (6)

Country Link
US (1) US20240288435A1 (https=)
EP (1) EP4279606A4 (https=)
JP (1) JP7808059B2 (https=)
KR (1) KR20230131222A (https=)
CN (1) CN116761895A (https=)
WO (1) WO2022154045A1 (https=)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008539694A (ja) 2005-04-25 2008-11-20 国立大学法人山梨大学 Ｃｌｅｃ−２シグナル伝達により止血疾患を治療するための組成物および方法
WO2012128082A1 (ja) 2011-03-22 2012-09-27 公益財団法人がん研究会 マウス抗Ａｇｇｒｕｓモノクローナル抗体
JP2014070942A (ja) 2012-09-28 2014-04-21 Mitsubishi Chemical Medience Corp 可溶型ｃｌｅｃ−２に基づく血小板活性化測定方法
WO2017027379A1 (en) 2015-08-07 2017-02-16 Thomas Helledays Stiftelse För Medicinsk Forskning Method for diagnosisng cancer or cancer-associated thrombosis by measuring levels of h3cit in plasma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2610910A1 (en) 2005-06-09 2006-12-21 Paul H. Mcpherson Methods and compositions for the diagnosis of venous thromboembolic disease
FR3048001B1 (fr) 2016-02-18 2018-02-09 Diagnostica Stago Methode de dosage des d-dimeres specifiques de la maladie thromboembolique veineuse
EP4113524A4 (en) * 2020-02-28 2024-03-06 LSI Medience Corporation METHOD FOR MEASURING PLATELE ACTIVATION BASED ON SOLUBLE CLEC-2 AND PLATELE COUNT

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008539694A (ja) 2005-04-25 2008-11-20 国立大学法人山梨大学 Ｃｌｅｃ−２シグナル伝達により止血疾患を治療するための組成物および方法
WO2012128082A1 (ja) 2011-03-22 2012-09-27 公益財団法人がん研究会 マウス抗Ａｇｇｒｕｓモノクローナル抗体
JP2014070942A (ja) 2012-09-28 2014-04-21 Mitsubishi Chemical Medience Corp 可溶型ｃｌｅｃ−２に基づく血小板活性化測定方法
WO2017027379A1 (en) 2015-08-07 2017-02-16 Thomas Helledays Stiftelse För Medicinsk Forskning Method for diagnosisng cancer or cancer-associated thrombosis by measuring levels of h3cit in plasma

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
NAZARI, P. M. S. et al.，The role of podoplanin in cancer-associated thrombosis，Thrombosis research，2018年，Vol.164，pp.S34-S39
SHIRAI, T. et al.，CLEC-2 facilitates hematogeneous tumor metastasis and in vitro tumor growth, but not in vivo tumor growth，journal of thrombosis and haemostasis，2015年06月，Vol.13, No.S2，p.226
SUZUKI-INOUE K. et al.，Roles of the CLEC-2-podoplanin interaction in tumor progression，Platelets，2018年，Vol.28, No.8，pp.786-792
SUZUKI-INOUE, K. et al.，Platelets and cancer-associated thrombosis: focusing on the platelet activation receptor CLEC-2 and podoplanin，blood，2019年11月28日，Vol.134, No.22，pp.1912-1918
佐野誠 ほか，血漿sVCAM-1とANP上昇は膵癌関連血栓症/血栓塞栓症の危険予測因子である，膵臓，2020年，第35巻，第3号，p.A266
白井俊光，CLEC-2/Podoplaninによる血小板の癌進展機構，日本血栓止血学会誌，2020年，Vol.31, No.4，pp.452-459
長田誠，血中ｓＣＬＥＣ－２測定法の臨床応用と実用化に向けた検討，科学研究費助成事業 研究成果報告書 [online]，2016年，[retrieved on 2022.02.08], Retrieved from the Internet: <URL: https://kaken.nii.ac.jp/ja/file/KAKENHI-PROJECT-25460677/25460677seika.pdf>

Also Published As

Publication number Publication date
CN116761895A (zh) 2023-09-15
US20240288435A1 (en) 2024-08-29
EP4279606A1 (en) 2023-11-22
EP4279606A4 (en) 2024-12-18
KR20230131222A (ko) 2023-09-12
WO2022154045A1 (ja) 2022-07-21
JPWO2022154045A1 (https=) 2022-07-21

Similar Documents

Publication Publication Date Title
Tian et al. The diagnostic value of serum C-reactive protein, procalcitonin, interleukin-6 and lactate dehydrogenase in patients with severe acute pancreatitis
Blann et al. Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or Type II diabetes
Shorr et al. D-dimer assay predicts mortality in critically ill patients without disseminated intravascular coagulation or venous thromboembolic disease
CN115190973B (zh) 基于可溶性clec-2与血小板数的血小板活化测定方法
JP6639392B2 (ja) 胎盤成長因子２の選択的測定法
CN108780093A (zh) 作为膀胱癌标志物的嗜铬粒蛋白a
Ando et al. Elevated ratio of C-type lectin-like receptor 2 level and platelet count (C2PAC) aids in the diagnosis of post-operative venous thromboembolism in IDH-wildtype gliomas
CN101460852A (zh) Mrp8/14水平用于鉴别个体处于急性冠状动脉综合症风险中的应用
Ding et al. Inflammatory markers differentiate cerebral venous sinus thrombosis from mimics
Karpińska et al. A prothrombotic state and denser clot formation in patients following acute limb ischemia of unknown cause
JP7808059B2 (ja) 可溶型ｃｌｅｃ２を用いた癌患者における血栓症リスクの予測方法
WO2020202241A1 (ja) 動脈硬化及び動脈硬化関連疾患マーカー
EP4350350A1 (en) Method for assessing risk of hemorrhagic stroke using soluble clec2
Lorente et al. High serum soluble fas ligand levels in non-survivor traumatic brain injury patients
EP4636404A2 (en) Method for evaluating risk of acute cerebral vascular disease using soluble clec2
El-Akabawy et al. Prognostic value of vascular endothelial growth factor in sepsis syndrome
WO2019027853A1 (en) DETECTION OF HIGH-RISK ARTERIAL THROMBO-EMBOLIC DISEASES BY COAGULATION AND HEMOSTATIC ACTIVATION MARKERS
Abdulaziz et al. Fecal Calgranulin C a Novel Noninvasive Marker in Predicting Activity and Severity of Ulcerative Colitis Compared with Colonoscopy.
Hunt et al. Venous thromboembolism and thrombophilia testing
Mahmoud et al. Reliability of plasma von Willebrand factor antigen in prediction of esophageal varices in patients with liver cirrhosis
Otero et al. Biomarkers of Venous Thromboembolism Recurrence after Discontinuation of Low Molecular Weight Heparin Treatment for Cancer-Associated Thrombosis (HISPALIS-Study). Cancers 2022, 14, 2771
HK40085757A (en) Method for measuring platelet activation based on soluble clec-2 and platelet count
Singh et al. Plasma vascular endothelial growth factors A and C in patients undergoing prostatic biopsy and TURP for suspected prostatic neoplasia
Wang et al. Predictive value of combined CRP/ALB ratio and DD/FIB ratio for MODS in patients with severe polytrauma.
Martin et al. Alexander Gombert1, Drosos Kotelis1, Marcia V. Rückbeil2, Mohammad Barbati1

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20240205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241021

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241021

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251211

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260106

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260116

R150 Certificate of patent or registration of utility model

Ref document number: 7808059

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150